Kyntra Bio, Inc. (KYNB)
5.36
-0.20
(-3.68%)
USD |
NASDAQ |
Oct 15, 16:00
5.37
+0.01
(+0.19%)
After-Hours: 20:00
Kyntra Bio Cash from Operations (TTM) : -38.05M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.05M |
| March 31, 2026 | -21.38M |
| December 31, 2025 | -4.82M |
| September 30, 2025 | -16.96M |
| June 30, 2025 | -23.49M |
| March 31, 2025 | -76.04M |
| December 31, 2024 | -138.00M |
| September 30, 2024 | -125.85M |
| June 30, 2024 | -202.02M |
| March 31, 2024 | -272.72M |
| December 31, 2023 | -315.02M |
| September 30, 2023 | -349.21M |
| June 30, 2023 | -316.56M |
| March 31, 2023 | -239.05M |
| December 31, 2022 | -145.93M |
| September 30, 2022 | -148.38M |
| June 30, 2022 | -52.24M |
| March 31, 2022 | -45.72M |
| December 31, 2021 | -82.23M |
| September 30, 2021 | -34.50M |
| June 30, 2021 | -80.10M |
| March 31, 2021 | 96.10M |
| December 31, 2020 | 81.60M |
| September 30, 2020 | 43.78M |
| Date | Value |
|---|---|
| June 30, 2020 | 17.65M |
| March 31, 2020 | -160.67M |
| December 31, 2019 | -78.70M |
| September 30, 2019 | -51.12M |
| June 30, 2019 | -15.40M |
| March 31, 2019 | -21.72M |
| December 31, 2018 | -76.18M |
| September 30, 2018 | -60.45M |
| June 30, 2018 | -87.19M |
| March 31, 2018 | -72.04M |
| December 31, 2017 | -67.54M |
| September 30, 2017 | -83.66M |
| June 30, 2017 | -67.05M |
| March 31, 2017 | -2.968M |
| December 31, 2016 | 7.108M |
| September 30, 2016 | -14.34M |
| June 30, 2016 | -50.56M |
| March 31, 2016 | 6.225M |
| December 31, 2015 | -18.57M |
| September 30, 2015 | -2.565M |
| June 30, 2015 | 4.033M |
| March 31, 2015 | -4.255M |
| December 31, 2014 | 22.41M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Vericel Corp. | 69.67M |
| Nektar Therapeutics | -233.79M |
| Capricor Therapeutics, Inc. | -104.00M |
| ARS Pharmaceuticals, Inc. | -196.40M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |